Browse by ▼

Elan

  • Value Investor Seth Klarman's Shakeups

    By Marshall Hargrave - May 22, 2013 | Tickers: AIG, BP, DTV, ELN, ORCL

    Seth Klarman's Baupost Group, led by the famed value investor and author of Margin of Safety, recently revealed its public equity portfolio in its quarterly filing with the SEC. Klarman founded Baupost in 1983, and now has assets under management of nearly $30 billion. Outlined below are five takeaways from Baupost's portfolio, which include some interesting additions (check out Klarman's cheap stock picks).

    Baupost kept BP (NYSE: BPmore »)

  • Flush With Cash, Elan Goes on a Buying Spree

    By Diane Alter - May 20, 2013 | Tickers: BIIB, ELN, NVS

    Call it the luck of the Irish.

    Prospects have been glum for Elan Corp (NYSE: ELN), but the Irish pharmaceutical company is showing some real promise.

    After suffering a serious setback last July, when results for bapineuzumab, an Alzheimer’s therapy in development with Pfizer and Johnson & Johnson, were disappointing, many questioned its survival as a stand alone company. 

    You see, the failure of that drug left Elan with just more »

  • Who Benefits From This Market Moving Biotechnology Partnership?

    By Brian Nichols - May 14, 2013 | Tickers: ELN, GSK, THRX

    Back towards the end of April 2013, Theravance (NASDAQ: THRX) surprised everyone when it announced plans to split into two separate companies. The two companies will split its independent biopharmaceuticals operations and its respiratory assets (including the recently approved BREO ELLIPTA) partnered with GlaxoSmithKline (NYSE: GSK). Since this announcement, news of yet another partnership with Elan (NYSE: ELN) might leave investors confused as to the direction of the company. My more »

  • Why Did This Biotech Soar?

    By Brandy Betz - May 13, 2013 | Tickers: ELN, GSK, THRX

    Theravance (NASDAQ: THRX) shares soared over 14% early Monday upon news that Elan (NYSE: ELN) will pay $1 billion for a  quartet of development stage respiratory drugs. The payment will give Elan a cut of potential future royalties to the drugs -- most of which Theravance developed with GlaxoSmithKline (NYSE: GSK).

    What does this deal mean for the companies involved -- and is Elan getting its money’s worth?

    COPD breathes easier more »

  • Buybacks, Takeovers and a Potentially Lucrative Drug

    By Mike Thiessen - April 24, 2013 | Tickers: BIIB, ELN, PFE

    Irish drug-maker Elan Pharmaceuticals (NYSE: ELN) has been at the center of fervent speculation from longs and shorts alike. After offloading a potential blockbuster drug called Tysabri to a smaller competitor, the company has been fighting off a takeover bid from privately held Royalty Pharma. While it is entirely possible that Elan will eventually agree to be taken private by Royalty, both companies have refused to compromise on key aspects more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan Corp. (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from $6 more »

  • Why Elan Shouldn’t Take Royalty Pharma’s Sweetened Bid

    By Diane Alter - April 16, 2013 | Tickers: BIIB, ELN, PRTA

    After years of being plagued by a waning stock price, FDA regulatory issues and safety concerns over its blockbuster drug, its finally good to be Elan (NYSE: ELN).

    Shunning a February $11 per share takeover bid from U.S. based pharmaceutical investment firm Royalty Pharma, Irish based Elan got a sweetened offer of up to $12 a share. The new deal values Elan at $7.3 billion, up from $6 more »

  • These Drug Partners are Headed in Opposite Directions

    By Robert Hanley - March 7, 2013 | Tickers: BIIB, ELN, TEVA

    Biogen Idec (NASDAQ: BIIB) and Elan Pharmaceuticals (NYSE: ELN) have partnered for more than a decade to win a big share of the multiple sclerosis (MS) drug market.  While their drug Tysabri has achieved some commercial success, everyone is chasing Teva Pharmaceuticals (NYSE: TEVA) and its MS drug Copaxone that controls roughly 40% of the domestic market.  Now, though, it looks like Biogen wants to go it alone, with a more »

  • Elan Received Buyout Bid Before Buyback

    By Diane Alter - February 25, 2013 | Tickers: BIIB, ELN, PRTA

    When Elan (NYSE: ELN) sold its stake in the blockbuster selling multiple sclerosis drug Tysabri to partner Biogen (NASDAQ: BIIB) in early February, many investors at both companies were left questioning the deal and the motive.

    Dublin, Ireland based Elan pocketed $3.25 billion in the sale (on which it will pay little tax) and also inked a royalty payment plan for future sales of the dynamic drug. The hefty more »

  • Why Elan Cut Its Ties To Tysabri

    By Diane Alter - February 12, 2013 | Tickers: BIIB, ELN, PRTA

    Editor's Note: The original article referenced shareholders would receive one share of Prothena for every share of Elan. That was incorrect, shareholders received one share of Prothena for 41 shares of Elan. This version has been corrected and Motley Fool apologizes for the error.

    Elan (NYSE: ELN) just announced a restructuring of its Tysabri collaboration with Biogen Idec (NASDAQ: BIIB) going from a 50/50 collaboration to an upfront more »

  • With Abbott's Spinoff Around the Corner, Should You Buy In?

    By Jordo Bivona - December 3, 2012 | Tickers: ABT, BMY, ELN, LLY, JNJ

    The highly publicized Abbott Laboratories (NYSE: ABT) spinoff is coming in roughly one month. The healthcare giant will spin off its proprietary pharmaceutical business segment into a new company, AbbVie.  The remaining segments of the business will remain a part of Abbott Laboratories. Will this turn out to be a good move for investors? Should investors buy into the stock now?  

    One of the most attractive aspects of investing in more »

  • Slaying the Alzheimer Demon

    By Karen Rogers - September 13, 2012 | Tickers: BAX, ELN, PFE, RHHBY

    This morning a husband woke up and couldn’t recognize his wife’s face.  An elderly mother stares blankly at her daughter, vainly trying to remember her child’s name. 

    This is the evil of Alzheimer’s, an insidious disease which robs families and friends of their loved ones while they’re still alive.  According to the Alzheimer Association, it will afflict more than 5.4 million Americans this year more »

  • Should Investors be Buying Eli Lilly on News?

    By Douglas Ehrman - August 31, 2012 | Tickers: ELN, LLY, JNJ, PFE

    Last week included two major news items for drug maker Eli Lilly & Co. (NYSE: LLY). Ringing in at the top of the audible gasp scale was the announcement that despite failing the primary study criteria in two late stage trials, the company’s development-stage Alzheimer’s drug was shown to slow the decline in cognitive function, particularly in mild cases. Of perhaps greater investment importance was the affirmation by the more »

  • Clinical Trial of New Johnson & Johnson Alzheimer's Drug Fails

    By Muhammad Bazil - July 31, 2012 | Tickers: ELN, FRX, JNJ, PFE

    New Jersey-based healthcare products and consumer packaged goods manufacturer Johnson & Johnson (NYSE: JNJ), announced late on Monday that one group of a Phase II clinical trial of its new drug for the treatment of Alzheimer's disease, bapineuzumab, failed to show that the drug slowed the progression of the disease.  A similar statement was also concurrently issued by Pfizer, Inc. (NYSE: PFE), which acquired an interest in the drug, along more »

  • Take the Long Road with Alkermes

    By Brandy Betz - February 5, 2012 | Tickers: ALKS, AMLN, BMY, ELN

    Biopharmaceutical company Alkermes (NASDAQ: ALKS) achieved a revenue increase of 185.7% in the third quarter of fiscal 2012, the first full quarter since the company acquired the drug delivery arm of Elan (NYSE: ELN). Zacks had predicted revenues of $113.0 million, 11% below the reported $125.6 million. The company also outperformed Zacks’ estimated 21 cents per share loss with a reported one cent per share loss. Though more »

  • Price The Market Part 32 - Skip the Financials

    By Glen Bradford - January 7, 2012 | Tickers: ELN, HSP, IBM, ISRG, JNJ

    Begin: Hi, my name is Glen Bradford. Welcome to the Financials part of my quest of Pricing the S&P500. This is the hard stuff, so to speak, as far as I'm concerned. Before I begin you might want to read my brief thoughts here.

    End: I sat down and priced out 20 of these financial companies. After doing so I came to a brief realization... I was not more »